Characterizing tumor-infiltrating lymphocytes in resectable early stage NSCLC
LUX-Lung 7: Phase 2b trial of first-line afatinib versus gefitinib for EGFR mutation-positive NSCLC
Durvalumab: the new standard of care for NSCLC?
Targeted therapies for advanced NSCLC
Progress in the treatment of ALK-positive non-small cell lung cancer